Ankündigung • May 29
China Risun Group Limited Declares Final Dividend for the Year Ended December 31, 2025, Payable on June 30, 2026 China Risun Group Limited announced at the AGM held on May 29, 2026, approved final dividend of RMB0.19 cents per share of the Company to be paid in Hong Kong dollars of an amount of HK0.22 cents per share of the Company for the year ended December 31, 2025 to the Shareholders whose names appear on the register of members of the Company on June 12, 2026 (the "Record Date"), and the payment date is expected to be June 30, 2026. Declared Dividend • Apr 30
Final dividend of HK$0.0022 announced Shareholders will receive a dividend of HK$0.0022. Ex-date: 8th June 2026 Payment date: 30th June 2026 Dividend yield will be 0.1%, which is lower than the industry average of 8.1%. Payout Ratios Payout ratio: 29%. Cash payout ratio: 0.4687%. New Risk • Apr 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.0x net interest cover). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Large one-off items impacting financial results. New Risk • Apr 02
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 86% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.0x net interest cover). Minor Risk Large one-off items impacting financial results. Ankündigung • Mar 30
China Risun Group Limited, Annual General Meeting, May 29, 2026 China Risun Group Limited, Annual General Meeting, May 29, 2026. Reported Earnings • Mar 30
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥0.013 (up from CN¥0.005 in FY 2024). Revenue: CN¥39.3b (down 17% from FY 2024). Net income: CN¥58.0m (up 188% from FY 2024). Profit margin: 0.1% (up from 0% in FY 2024). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 9.8%. Earnings per share (EPS) also missed analyst estimates by 33%. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 6.5% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance. Ankündigung • Mar 17
China Risun Group Limited to Report Fiscal Year 2025 Results on Mar 27, 2026 China Risun Group Limited announced that they will report fiscal year 2025 results on Mar 27, 2026 Declared Dividend • Sep 03
First half dividend of HK$0.0022 announced Shareholders will receive a dividend of HK$0.0022. Ex-date: 12th September 2025 Payment date: 30th September 2025 Dividend yield will be 1.1%, which is lower than the industry average of 8.1%. Reported Earnings • Sep 02
First half 2025 earnings released: EPS: CN¥0.007 (vs CN¥0.025 in 1H 2024) First half 2025 results: EPS: CN¥0.007 (down from CN¥0.025 in 1H 2024). Revenue: CN¥20.5b (down 19% from 1H 2024). Net income: CN¥28.6m (down 74% from 1H 2024). Profit margin: 0.1% (down from 0.4% in 1H 2024). Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance. Ankündigung • Aug 19
China Risun Group Limited to Report First Half, 2025 Results on Aug 29, 2025 China Risun Group Limited announced that they will report first half, 2025 results on Aug 29, 2025 Buy Or Sell Opportunity • Jul 25
Now 21% undervalued The stock has been flat over the last 90 days, currently trading at HK$2.53. The fair value is estimated to be HK$3.20, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.8% over the last 3 years. Earnings per share has declined by 77%. For the next 3 years, revenue is forecast to grow by 5.5% per annum. Earnings are also forecast to grow by 58% per annum over the same time period. Buy Or Sell Opportunity • Jul 04
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 4.5% to HK$2.52. The fair value is estimated to be HK$3.21, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.8% over the last 3 years. Earnings per share has declined by 77%. For the next 3 years, revenue is forecast to grow by 5.5% per annum. Earnings are also forecast to grow by 58% per annum over the same time period. Buy Or Sell Opportunity • Jun 13
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 7.7% to HK$2.52. The fair value is estimated to be HK$3.16, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.8% over the last 3 years. Earnings per share has declined by 77%. For the next 3 years, revenue is forecast to grow by 5.5% per annum. Earnings are also forecast to grow by 58% per annum over the same time period. Upcoming Dividend • Jun 02
Upcoming dividend of HK$0.024 per share Eligible shareholders must have bought the stock before 09 June 2025. Payment date: 30 June 2025. The company last paid an ordinary dividend in April 2019. The average dividend yield among industry peers is 3.6%. Ankündigung • May 30
China Risun Group Limited Approves and Declares Special Dividend, Expected Payable on June 30, 2025 China Risun Group Limited at its AGM held on May 30, 2025 approved and declared a special dividend of RMB 2.22 cents per share (the "Special Dividend") to be paid in Hong Kong dollars of an amount of HK 2.40 cents per share (tax-inclusive) out of the share premium account of the Company. As the resolution for the payment of the Special Dividend was duly passed at the AGM, the Company will pay the Special Dividend in cash for the year ended December 31, 2024 to the Shareholders whose names appear on the register of members of the Company on June 13, 2025 (the "Record Date"), and the payment date is expected to be June 30, 2025. Ex-dividend date is 9 June 2025. Buy Or Sell Opportunity • May 19
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 13% to HK$2.39. The fair value is estimated to be HK$3.07, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.8% over the last 3 years. Earnings per share has declined by 77%. For the next 3 years, revenue is forecast to grow by 5.5% per annum. Earnings are also forecast to grow by 58% per annum over the same time period. Reported Earnings • May 04
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.005 (down from CN¥0.20 in FY 2023). Revenue: CN¥47.5b (up 3.2% from FY 2023). Net income: CN¥20.1m (down 98% from FY 2023). Profit margin: 0% (down from 1.9% in FY 2023). Revenue missed analyst estimates by 5.3%. Earnings per share (EPS) also missed analyst estimates by 92%. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance. Declared Dividend • May 01
Final dividend of HK$0.024 announced Shareholders will receive a dividend of HK$0.024. Ex-date: 9th June 2025 Payment date: 30th June 2025 Dividend yield will be 1.3%, which is lower than the industry average of 8.1%. Recent Insider Transactions • Apr 13
CEO & Chairman recently bought HK$1.1m worth of stock On the 7th of April, Xuegang Yang bought around 425k shares on-market at roughly HK$2.49 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$2.3m. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$45m worth in shares. New Risk • Apr 01
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 42% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.04% net profit margin). Reported Earnings • Mar 30
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.005 (down from CN¥0.20 in FY 2023). Revenue: CN¥47.5b (up 3.2% from FY 2023). Net income: CN¥20.1m (down 98% from FY 2023). Profit margin: 0% (down from 1.9% in FY 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 5.3%. Earnings per share (EPS) also missed analyst estimates by 92%. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 6.8% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance. Ankündigung • Mar 29
China Risun Group Limited, Annual General Meeting, May 30, 2025 China Risun Group Limited, Annual General Meeting, May 30, 2025. Buy Or Sell Opportunity • Mar 25
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 13% to HK$2.48. The fair value is estimated to be HK$3.10, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has declined by 59%. Revenue is forecast to grow by 17% in 2 years. Earnings are forecast to grow by 147% in the next 2 years. Ankündigung • Mar 18
China Risun Group Limited to Report Fiscal Year 2024 Results on Mar 28, 2025 China Risun Group Limited announced that they will report fiscal year 2024 results on Mar 28, 2025 Ankündigung • Dec 27
China Risun Group Limited has completed a Follow-on Equity Offering in the amount of HKD 156 million. China Risun Group Limited has completed a Follow-on Equity Offering in the amount of HKD 156 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 52,000,000
Price\Range: HKD 3
Transaction Features: Subsequent Direct Listing Recent Insider Transactions • Dec 24
CEO & Chairman recently bought HK$4.6m worth of stock On the 20th of December, Xuegang Yang bought around 2m shares on-market at roughly HK$2.85 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$25m worth in shares. Ankündigung • Oct 10
China Risun Group Limited Announces Liu Xiaofeng as Independent Non-Executive Director and A Member of the Audit Committee The Board of China Risun Group Limited announced that Dr Liu Xiaofeng has been appointed as an INED and a member of the Audit Committee, effective from October 10, 2024. Dr. Liu Xiaofeng, aged 62, obtained a master ' s degree and a Ph.D. in development economics from University of Cambridge in October 1988 and May 1994 respectively. He also obtained a master's degree in Development Studies from the University of Bath in December 1987, and a bachelor's degree in economics from Southwest University of Finance and Economics in China (previously known as Sichuan Institute of Finance and Economics) in July 1983. Dr. Liu has approximately 32 years of experience in corporate finance and has worked in various international financial institutions since 1993, including N M Rothschild & Sons Limited, N M Rothschild & Sons (Hong Kong) Limited, JPMorgan Chase, DBS Asia Capital Limited, China Resources Capital Holdings Company Limited and UBS Securities Co., Limited. He also served as an independent non-executive director at Haier Electronics Group Co. Ltd. (stock code: 1169) from June 2007 to June 2014, at Hisense Home Appliances Group Co. Ltd. (stock code: 921) from September 2017 to August 2018, at Honghua Group Limited (stock code: 196) from January 2008 to November 2021, at AAG Energy Holdings Limited (stock code: 2686, delisted in July 2023) from August 2018 to August 2023, and at Cinda International Holdings Limited (stock code: 111) from July 2016 to July 2024. Currently, he has been an independent non-executive director at KunLun Energy Company Limited (stock code: 135) since April 2004, at Sunfonda Group Holdings Limited (stock code: 1771) since May 2017, at Logory Logistics Technology Co. Ltd. (stock code: 2482) since March 2023. Moreover, Dr. Liu has been the vice president of the China Independent Non-executive Directors Association since August 2023. Reported Earnings • Sep 29
First half 2024 earnings released: EPS: CN¥0.025 (vs CN¥0.16 in 1H 2023) First half 2024 results: EPS: CN¥0.025 (down from CN¥0.16 in 1H 2023). Revenue: CN¥25.2b (up 21% from 1H 2023). Net income: CN¥111.9m (down 84% from 1H 2023). Profit margin: 0.4% (down from 3.4% in 1H 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Major Estimate Revision • Sep 05
Consensus EPS estimates fall by 71% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥48.7b to CN¥48.2b. EPS estimate also fell from CN¥0.207 per share to CN¥0.06 per share. Net income forecast to grow 62% next year vs 24% growth forecast for Chemicals industry in Hong Kong. Consensus price target of HK$4.10 unchanged from last update. Share price rose 3.1% to HK$2.96 over the past week. Reported Earnings • Aug 30
First half 2024 earnings released: EPS: CN¥0.025 (vs CN¥0.16 in 1H 2023) First half 2024 results: EPS: CN¥0.025 (down from CN¥0.16 in 1H 2023). Revenue: CN¥25.2b (up 21% from 1H 2023). Net income: CN¥111.9m (down 84% from 1H 2023). Profit margin: 0.4% (down from 3.4% in 1H 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. Ankündigung • Aug 28
China Risun Group Limited Announces Ordinary Interim (Semi-Annual) Dividend for the Six Months Ended June 30, 2024, Payable on 30 September 2024 China Risun Group Limited announced ordinary interim (semi-annual) dividend of RMB 0.0078 per share for the six months ended June 30, 2024. Ex-dividend date: 09 September 2024. Record date: 13 September 2024. Payment date: 30 September 2024. Ankündigung • Aug 14
China Risun Group Limited to Report First Half, 2024 Results on Aug 23, 2024 China Risun Group Limited announced that they will report first half, 2024 results on Aug 23, 2024 Recent Insider Transactions • Jul 23
CEO & Chairman recently bought HK$1.5m worth of stock On the 16th of July, Xuegang Yang bought around 500k shares on-market at roughly HK$2.99 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$13m. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$48m worth in shares. Ankündigung • Jul 15
China Risun Group Limited Announces Board and Committee Changes China Risun Group Limited announced that Mr. Kang Woon (Mr. Kang) resigned as an independent non-executive director of the company (INED), the chairman of the remuneration committee and a member of each of the nomination committee and audit committee under the board on July 15, 2024 as he received a bankruptcy order dated June 25, 2024 issued by the High Court of Hong Kong against him. Mr. Kang further informed the company that he is considering taking all necessary actions to discharge his bankruptcy order, including, but not limited to, exploring legal options in Hong Kong, such as filing an appeal with the High Court of Hong Kong. Change of composition of board committees: To fill the vacancies of a member of the nomination committee and the chairman of the remuneration committee under the Board, the Board resolved to appoint Mr. Wang Yinping as a member of the nomination committee; and appoint Mr. Wang Yinping, an existing committee member, as the chairman of the remuneration committee and Mr. Li Qinghua as a member of the remuneration committee. Recent Insider Transactions • Jul 10
CEO & Chairman recently bought HK$1.1m worth of stock On the 4th of July, Xuegang Yang bought around 368k shares on-market at roughly HK$3.02 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$13m. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$46m worth in shares. Recent Insider Transactions • Jun 26
CEO & Chairman recently bought HK$13m worth of stock On the 21st of June, Xuegang Yang bought around 4m shares on-market at roughly HK$3.00 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$44m worth in shares. Recent Insider Transactions • Jun 15
CEO & Chairman recently bought HK$1.1m worth of stock On the 11th of June, Xuegang Yang bought around 358k shares on-market at roughly HK$3.02 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$1.3m. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$29m worth in shares. Recent Insider Transactions • Jun 11
CEO & Chairman recently bought HK$1.3m worth of stock On the 3rd of June, Xuegang Yang bought around 424k shares on-market at roughly HK$3.00 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$28m worth in shares. Ankündigung • May 31
China Risun Group Limited Approves Final Ordinary Dividend for the Fiscal Year Ended 31 December 2023, Payable on 28 June 2024 China Risun Group Limited at its AGM held on 30 May 2024 approved Final Ordinary dividend for the fiscal year ended 31 December 2023. Dividend declared is RMB 0.012 per share. Ex-dividend date is 07 June 2024. Record date is 14 June 2024. Payment date is 28 June 2024. Upcoming Dividend • May 31
Upcoming dividend of HK$0.013 per share Eligible shareholders must have bought the stock before 07 June 2024. Payment date: 28 June 2024. Payout ratio is a comfortable 31% but the company is paying out more than the cash it is generating. Trailing yield: 2.2%. Lower than top quartile of Hong Kong dividend payers (7.6%). Lower than average of industry peers (4.7%). Buy Or Sell Opportunity • May 10
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 6.6% to HK$3.24. The fair value is estimated to be HK$2.69, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years. Earnings per share has declined by 33%. Revenue is forecast to grow by 42% in 2 years. Earnings are forecast to grow by 341% in the next 2 years. Reported Earnings • Apr 30
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.20 (down from CN¥0.42 in FY 2022). Revenue: CN¥46.1b (up 6.8% from FY 2022). Net income: CN¥860.8m (down 54% from FY 2022). Profit margin: 1.9% (down from 4.3% in FY 2022). Revenue missed analyst estimates by 10%. Earnings per share (EPS) also missed analyst estimates by 63%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. Declared Dividend • Apr 29
Final dividend increased to HK$0.013 Dividend of HK$0.013 is 32% higher than last year. Ex-date: 7th June 2024 Payment date: 28th June 2024 Dividend yield will be 2.1%, which is lower than the industry average of 8.1%. Sustainability & Growth Dividend is well covered by both earnings (31% earnings payout ratio) and cash flows (12% cash payout ratio). The dividend has decreased over the past 56 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 140% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Ankündigung • Apr 28
China Risun Group Limited, Annual General Meeting, May 30, 2024 China Risun Group Limited, Annual General Meeting, May 30, 2024, at 10:00 China Standard Time. Location: Room 2001, 20/F., Sino Plaza, 255 Gloucester Road, Causeway Bay, Hong Kong Causeway Bay Hong Kong Agenda: To consider and approve the report of the board of directors of the Company for the year ended December 31, 2023; to consider and approve the audited financial statements of the Company and the independent auditor's report for the year ended December 31, 2023; to re-elect Ms. Lu Xiaomei as an executive director of the Company; to re-elect Mr. Li Qinghua as an executive director of the Company; to re-elect Mr. Wang Nianping as an executive director of the Company; to authorize the board of directors of the Company to fix the remuneration of the directors of the Company for the year ending December 31, 2024; and to consider other business matters. Ankündigung • Apr 26
China Risun Group Limited Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 28 June 2024 China Risun Group Limited proposed final dividend of RMB 0.012 per share for the year ended December 31, 2023. Date of shareholders' approval is 30 May 2024, Ex-dividend date is 07 June 2024, Record date is 14 June 2024 and Payment date is 28 June 2024. Reported Earnings • Mar 16
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.19 (down from CN¥0.42 in FY 2022). Revenue: CN¥46.1b (up 6.8% from FY 2022). Net income: CN¥860.8m (down 54% from FY 2022). Profit margin: 1.9% (down from 4.3% in FY 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 10%. Earnings per share (EPS) also missed analyst estimates by 63%. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Ankündigung • Mar 15
China Risun Group Limited Announces Final Cash Dividend for the Year Ended 31 December 2023, Payable on 28 June 2024 China Risun Group Limited announced final cash dividend of RMB 0.012 per share for the year ended 31 December 2023. Payment date is 28 June 2024. Ankündigung • Mar 02
China Risun Group Limited to Report Fiscal Year 2023 Results on Mar 14, 2024 China Risun Group Limited announced that they will report fiscal year 2023 results on Mar 14, 2024 Recent Insider Transactions • Dec 03
CEO & Chairman recently bought HK$3.9m worth of stock On the 30th of November, Xuegang Yang bought around 1m shares on-market at roughly HK$3.18 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$143m worth in shares. Recent Insider Transactions • Nov 10
CEO & Chairman recently bought HK$3.1m worth of stock On the 7th of November, Xuegang Yang bought around 968k shares on-market at roughly HK$3.19 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$3.8m. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$135m worth in shares. Recent Insider Transactions • Oct 23
CEO & Chairman recently bought HK$1.6m worth of stock On the 17th of October, Xuegang Yang bought around 502k shares on-market at roughly HK$3.17 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$3.8m. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$136m worth in shares. Recent Insider Transactions • Sep 16
CEO & Chairman recently bought HK$1.3m worth of stock On the 15th of September, Xuegang Yang bought around 400k shares on-market at roughly HK$3.24 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$122m worth in shares. Upcoming Dividend • Sep 04
Upcoming dividend of HK$0.053 per share at 4.0% yield Eligible shareholders must have bought the stock before 11 September 2023. Payment date: 29 September 2023. Payout ratio is a comfortable 31% but the company is not cash flow positive. Trailing yield: 4.0%. Lower than top quartile of Hong Kong dividend payers (7.7%). Lower than average of industry peers (7.7%). Reported Earnings • Aug 27
First half 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.39 in 1H 2022) First half 2023 results: EPS: CN¥0.16 (down from CN¥0.39 in 1H 2022). Revenue: CN¥20.8b (down 7.5% from 1H 2022). Net income: CN¥715.7m (down 59% from 1H 2022). Profit margin: 3.4% (down from 7.7% in 1H 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Ankündigung • Aug 26
China Risun Group Limited Declares Ordinary Interim (Semi-Annual) Dividend for the Six Months Ended June 30, 2023, Payable on 29 September 2023 China Risun Group Limited declared ordinary interim (semi-annual) dividend of RMB 0.049 per share for the six months ended June 30, 2023. Ex-dividend date: 8 September 2023. Record date: 15 September 2023. Payment date: 29 September 2023. Ankündigung • Aug 16
China Risun Group Limited to Report First Half, 2023 Results on Aug 25, 2023 China Risun Group Limited announced that they will report first half, 2023 results on Aug 25, 2023 Price Target Changed • Jun 06
Price target decreased by 11% to HK$5.35 Down from HK$6.00, the current price target is an average from 2 analysts. New target price is 55% above last closing price of HK$3.46. Stock is down 7.0% over the past year. The company is forecast to post earnings per share of CN¥0.52 for next year compared to CN¥0.42 last year. Upcoming Dividend • Jun 05
Upcoming dividend of HK$0.01 per share at 4.3% yield Eligible shareholders must have bought the stock before 12 June 2023. Payment date: 30 June 2023. Payout ratio is a comfortable 32% but the company is not cash flow positive. Trailing yield: 4.3%. Lower than top quartile of Hong Kong dividend payers (7.8%). Lower than average of industry peers (7.5%). Ankündigung • May 31
China Risun Group Limited Announces Final Ordinary Dividend for the Year Ended December 31, 2022, Payable on or Before June 30, 2023 China Risun Group Limited announced final ordinary of RMB 0.009 dividend for the year ended December 31, 2022, payable on 30 June 2023, Record date is 16 June 2023 and Ex dividend: 12 June 2023. Recent Insider Transactions • May 09
CEO & Chairman recently bought HK$11m worth of stock On the 3rd of May, Xuegang Yang bought around 3m shares on-market at roughly HK$3.54 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$11m. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$98m worth in shares. Recent Insider Transactions • Apr 28
CEO & Chairman recently bought HK$11m worth of stock On the 24th of April, Xuegang Yang bought around 3m shares on-market at roughly HK$3.63 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$11m. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$66m worth in shares. Recent Insider Transactions • Apr 13
CEO & Chairman recently bought HK$6.7m worth of stock On the 6th of April, Xuegang Yang bought around 2m shares on-market at roughly HK$3.34 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$13m worth in shares. Reported Earnings • Apr 01
Full year 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.61 in FY 2021) Full year 2022 results: EPS: CN¥0.42 (down from CN¥0.61 in FY 2021). Revenue: CN¥43.1b (up 12% from FY 2021). Net income: CN¥1.86b (down 29% from FY 2021). Profit margin: 4.3% (down from 6.8% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 17% per year. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Non-Executive Director Yinping Wang was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Recent Insider Transactions • Nov 05
CEO & Chairman recently bought HK$3.0m worth of stock On the 28th of October, Xuegang Yang bought around 1m shares on-market at roughly HK$2.89 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$6.1m worth in shares. Buying Opportunity • Oct 31
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 9.5%. The fair value is estimated to be HK$3.61, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Earnings per share has grown by 18%. Buying Opportunity • Sep 26
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 13%. The fair value is estimated to be HK$4.03, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Earnings per share has grown by 18%. Upcoming Dividend • Sep 02
Upcoming dividend of HK$0.14 per share Eligible shareholders must have bought the stock before 09 September 2022. Payment date: 30 September 2022. Payout ratio is a comfortable 31% but the company is not cash flow positive. Trailing yield: 7.1%. Lower than top quartile of Hong Kong dividend payers (8.2%). Higher than average of industry peers (6.1%).